Filing Flows › Ultragenyx Pharmaceutical (RARE) › Q2 2026 › vs Q1 2026
Ultragenyx Pharmaceutical (RARE) Q2 2026 vs Q1 2026 (quarter over quarter)
Ultragenyx Pharmaceutical's revenue rose $78.0M (+57%) from $136M in Q1 2026 to $214M in Q2 2026. The biggest changes: Royalty +$55.0M (+117%); Product +$23.0M (+26%).
Ultragenyx Pharmaceutical, Q2 2026: revenue $214M (+28% year over year), operating margin -35.0%, net loss $92.0M, operating cash flow −$97.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $112M | $89.0M | $23.0M | +26% |
| Royalty | $102M | $47.0M | $55.0M | +117% |
| Revenue | $214M | $136M | $78.0M | +57% |
| Net loss | $92.0M | $185M | −$93.0M | -50% |
| Costs & expenses | $306M | $321M | −$15.0M | -5% |
| Operating costs | $289M | $305M | −$16.0M | -5% |
| Interest & other, net | $16.0M | $15.0M | $1.0M | +7% |
| Income tax | $1.0M | $1.0M | $0 | 0% |
| Research & development | $167M | $187M | −$20.0M | -11% |
| SG&A | $88.0M | $88.0M | $0 | 0% |
| Other operating costs | $34.0M | $30.0M | $4.0M | +13% |
| Operating cash sources | $139M | $205M | −$66.0M | -32% |
| Depreciation & amortization | $8.0M | $8.0M | $0 | 0% |
| Share-based compensation | $34.0M | $30K | $34.0M | 1,133× |
| Cash used in operations | $97.0M | $197M | −$100M | -51% |
| Net loss absorbed | $92.0M | $185M | −$93.0M | -50% |
| Working capital & other | $47.0M | $20.0M | $27.0M | +135% |
Questions
How much did Ultragenyx Pharmaceutical's revenue grow quarter over quarter in Q2 2026?
Ultragenyx Pharmaceutical's revenue rose $78.0M (+57%) from $136M in Q1 2026 to $214M in Q2 2026.
What drove Ultragenyx Pharmaceutical's revenue change in Q2 2026?
Royalty +$55.0M (+117%); Product +$23.0M (+26%).